ABIVAX press release
Abivax announces excellent efficacy and safety results after one year of treatment in the phase 2b maintenance study of ABX464 in ulcerative colitis.
The interim analysis shows a “best-in-class” clinical remission rate of 55.3% (overall analysis) for 217 patients with ulcerative colitis (UC), after daily oral administration of 50 mg of ABX464 for 48 weeks
In addition, at the end of the first year of maintenance treatment, a clinical remission rate of 65.3% (overall analysis) is achieved in the subgroup of 121 patients who benefited from at least
clinical response after the 8-week induction study
Endoscopic improvement and endoscopic remission at week 48 reach 61.8% and 33.6%, respectively (overall analyses)
The good safety and tolerability profile observed reinforces the potential of ABX464 to be prescribed as a chronic treatment
Final preparations for the international phase 3 clinical program with ABX464 in UC are underway, the inclusion of the first patients is planned for the third quarter of 2022